Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics of Acamprosate

  • Review Articles
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Acamprosate is a new psychotropic drug used in the treatment of alcohol (ethanol)-dependence. Recent studies suggest that acamprosate inhibits neuronal hyperexcitability by antagonising excitatory amino acids. It is available as a 333mg enteric-coated tablet, with a recommended dosage of 1.3 g/day for patients with a bodyweight <60kg and 2 g/day for patients with a bodyweight ≥60kg. Treatment with higher dose strength tablets 2 × 500mg twice daily is bioequivalent to treatment with the 2 × 333mg 3 times daily dosage regimen.

Acamprosate is absorbed via the paracellular route in the gastrointestinal tract. Absorption is rapid but limited after oral administration. At steady-state, acamprosate has a moderate distribution volume of about 20L. Acamprosate is not protein bound or metabolised. Half of the elimination of acamprosate occurs as unchanged acetyl-homotaurine in urine, the other half might be eliminated by biliary excretion.

The administration of the enteric-coated tablets showed a flip-flop mechanism with a terminal elimination half-life 10-fold higher than the 3-hour half-life reported after intravenous infusion. During repeated oral administration of 666mg 3 times daily, steady-state is reached after 5 to 7 days and leads to plasma concentrations ranging from 370 to 650 μg/L. The pharmacokinetics of acamprosate administered as an enteric-coated tablets are timesand dose-independent, and its accumulation ratio is about 2.4 at steady-state.

Acamprosate disposition does not differ between males and females. The pharmacokinetics of acamprosate are not modified in patients with hepatic insufficiency or chronic alcoholism. In contrast, renal insufficiency influences the elimination of acamprosate and it is, therefore, contraindicated under such circumstances.

Interaction studies have confirmed that when acamprosate is concomitantly administered with food, the amount absorbed is decreased. When combined with diazepam, disulfiram or alcohol, the pharmacokinetic disposition of acamprosate is not modified. Acamprosate does not influence the kinetics of diazepam, alcohol or imipramine and its metabolite desipramine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Saivin S, Hulot T, Theodor R, et al. Bioequivalence study for highly variable drugs: the example of acamprosate. Pharm Res. In press.

  2. Sass H, Potgieter AS, Lehert P. Results from a polled analysis of 11 European trials comparing acamprosate and placebo on the treatment of alcohol dependence. Alcohol Alcohol 1995; 30 (4): 551.

    Google Scholar 

  3. Paille F, Guelfi JD, Perkins A, et al. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 1995; 30 (2): 239–47.

    PubMed  CAS  Google Scholar 

  4. Whitworth AB, Fischer F, Lesch OM, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996; 347: 1438–42.

    Article  PubMed  CAS  Google Scholar 

  5. Poldrugo F, Chabac S, Lehert P, et al. Acamprosate in the longterm treatment of alcoholism: is its use recommended within the psycho-social approach? Alcohol Clin Exp Res 1994; 18(2): 43A.

    Google Scholar 

  6. Pelc I, Le Bon O, Verbanck P, et al. Calcium-acetylhomotaurinate for maintaining abstinence in weaned alcoholic patients: a placebo-controlled double-blind multicenter study. In: Novel pharmacological interventions in alcoholism. New York: Springer, 1992.

    Google Scholar 

  7. Chabenat C, Ladure P, Moore N, et al. Application of an analytical method to calcium acetylhomotaurinate determination. Arzneimittel Forschung 1989; 39 (II): 1413–4.

    PubMed  CAS  Google Scholar 

  8. Chabenat C, Ladure P, Moore N, et al. Determination of calcium acetylhomotaurinate by liquid chromatography with fluorimetric and electrochemical detection. J Chromatogr 1987; 414 (2): 417–22.

    Article  PubMed  CAS  Google Scholar 

  9. Girault J, Gobin P, Fourtillan JB. Determination of calcium acetylhomotaurinate in human plasma and urine by combined gas chromatography-negative-ion chemical ionization mass spectrometry. J Chromatogr 1990; 530: 295–305.

    Article  PubMed  CAS  Google Scholar 

  10. Littleton JM. Acamprosate in alcohol dependence: how does it work? Addiction 1995; 90: 1179–88.

    Article  PubMed  CAS  Google Scholar 

  11. Spanagel R, Zieglgänsberger W. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. TIPS 1997; 18: 54–9.

    PubMed  CAS  Google Scholar 

  12. Naassila M, Hammoumi S, Legrand E, et al. Mechanism of action of acamprosate. I. Characterisation of spermidine sensitive acamprosate binding site (ABS) in rat brain. Alcohol Clin Exp Res 1998; 22 (4): 802–9.

    CAS  Google Scholar 

  13. Al Qatari M, Bouchenafa O, Littleton J. Mechanism of action of acamprosate: II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res 1998; 22 (4): 810–4.

    CAS  Google Scholar 

  14. Daoust M, Legrand E, Gewiss M, et al. Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised rats. Pharmacol Biochem Behav 1992; 41 (4): 669–74.

    Article  PubMed  CAS  Google Scholar 

  15. Nalpas B, Dabadie H, Parot P, et al. L’acamprosate: de la pharmacologie à la clinique. Encéphale 1990; 16 (3): 175–9.

    PubMed  CAS  Google Scholar 

  16. Boismare F, Daoust M, Moore ND, et al. A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABAreceptors involved? Pharmacol Biochem Behav 1984; 21 (5): 787–9.

    Article  PubMed  CAS  Google Scholar 

  17. Le Magnen J, Tran G, Durlach J, et al. Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by Ca-acetyl homotaurinate. Alcohol 1987; 4 (2): 97–102.

    Article  PubMed  Google Scholar 

  18. Grant KA, Woolverton WL. Reinforcing and discriminative stimulus effects of Ca-acetyl homotaurinate in animals. Pharmacol Biochem Behav 1989; 32 (3): 607–11.

    Article  PubMed  CAS  Google Scholar 

  19. Wilde MI, Wagstaff AJ. Acamprosate: a review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 1997; 53 (6): 1038–53.

    Article  PubMed  CAS  Google Scholar 

  20. Besson J, Aeby F, Kasas A, et al. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 1998; 22 (3): 573–9.

    Article  PubMed  CAS  Google Scholar 

  21. Lipha. Campral, prescribing information. Lyon, France, 1995.

  22. Fourtillan JB. Pharmacokinetics of acetylhomotaurinate (AOTA) in young healthy volunteers subjects after single and multiple oral administrations of doses equal to 666 mg of calcium acetylhomotaurinate (AOTA-Ca). Lipha. France, 1990; AD 875 H. (Data on file).

  23. Jaillon P, Salvat M. Pharmacokinetics study of intravenous administration of AOTAL (calcium acetylhomotaurinate) at single doses of 10, 20 and 30 mg/kg. Lipha, France, 1991. (Data on file).

  24. Dewland PM. A rising dose tolerance and pharmacokinetic study of calcium bis acetyl homotaurine following single oral administration of a solution at four dose levels. Lipha, France, 1991. RD 298/17927. (Data on file).

  25. Fourtillan JB. Pharmacokinetics and relative bioavailabilities of acetylhomotaurinate (AOTA) after oral administration of a single dose equal to 666 mg of calcium acetylhomotaurinate (AOTA-Ca) in six young healthy volunteers, when given as aqueous solution and enteric coated tablets. Lipha, France, 1989; AD 864 H. (Data on file).

  26. Fourtillan JB. Influence of food on acetylhomotaurine pharmacokinetics after single oral administration of acamprosate. Lipha, France, 1992; AD 1011 H. (Data on file).

  27. Sennesael J. Acamprosate pharmacokinetic study after a single oral administration of 2 acamprosate tablets (2 × 333 mg) to subjects with normal or impaired renal function. Lipha, France, 1992; AOTA-CIN IR1-AD 1003 H. (Data on file).

  28. Dewland PM. Report of an investigation of the effect of ethanol upon the pharmacokinetics of acamprosate. Lipha, France, 1991; RD 298/17949. (Data on file).

  29. Dewland PM. Report of the comparison of the plasma pharmacokinetics of acamprosate following a single oral dose to equal numbers of men and women. Lipha, France, 1995; RD 298/20673. (Data on file).

  30. Haug G. Pharmacokinetic study of 2 acamprosate tablets (2x333 mg) in patients with different stages of impaired liver function compared to a control group of healthy volunteers. Lipha, France, 1992; 90235. (Data on file).

  31. Fourtillan JB. Research of pharmacokinetic interactions between diazepam and acamprosate when given in combination on multiple oral dosing. Lipha, France, 1995; AD 1126 H. (Data on file).

  32. Dewland PM. Report of the potential pharmacokinetic interaction of disulfiram with acamprosate. Lipha, France, 1995; RD 298/20828. (Data on file).

  33. Pelc I. Acamprosate pharmacokinetic study during the treatment of alcoholic patients following withdrawal. Lipha, France, 1993; AOTA-CIN PA1-AD 1054 H. (Data on file).

  34. Miguet J. Plasma kinetics of acamprosate after a single oral administration to patients with liver disease. Lipha, France, 1991; AOTA-CIN IHP 1. (Data on file).

  35. De Boer AG, Voorwinden H, Durbin P, et al. The influence of Acamprosate on the trans-epithelial-electrical resistance (TEER) and the paracellular transport across caco-2 monolayers [poster]. 6th European Congress of Biopharmaceutics and Pharmacokinetics; 1996 Apr 22–24; Athens.

  36. Houin G. Preliminary study of in vitro absorption of acamprosate with the everted gut sac method. Lipha, France, 1997; Acamprosate 97.026. (Data on file).

  37. Scott G. The metabolism and pharmacokinetics of 14C AOTA-Ca in man. Lipha, France, 1991; IRI 7488. (Data on file).

  38. Durbin P, Hulot T, Chabac S. Pharmacodynamics and pharmacokinetics of acamprosate: an overview. In: Soyka M, editor. Acamprosate in relapse prevention of alcoholism. Proceedings of the 1st Campral Symposium; 1995 Sep 3; Stuttgart: Springer, 1995: 47–64.

    Google Scholar 

  39. Lucker PL. A pilot study of the influence of AOTAL on the pharmacokinetics of ethyl alcohol. Lipha, France, 1989; 12/89–03 AL. (Data on file).

  40. Klots U, Antonin KH, Bieck PR. Comparison of the pharmacokinetics of diazepam after single and subchronic doses. Eur J Clin Pharmacol 1976; 10: 121–6.

    Article  Google Scholar 

  41. Kaplan SA, Jack ML, Alexander K, et al. Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administrations. J Pharm Sci 1973; 62 (11): 1789–96.

    Article  PubMed  CAS  Google Scholar 

  42. Fourtillan JB. Research of pharmacokinetic interactions between imipramine and acamprosate when given in combination on multiple oral dosing. Lipha, France, 1995; AD 1135 H. (Data on file).

  43. Aubin HJ, Lehert P, Beaupere B, et al. Tolérance de l’association de l’acamprosate aux médicaments du sevrage d’alcool. Essai multicentrique sur 591 alcooliques en sevrage. Alcoologie 1994; 16 (1): 32–41.

    Google Scholar 

  44. Aubin HJ, Lehert P, Beaupere B, et al. Tolerability of the combination of acamprosate with drugs used to prevent alcohol withdrawal syndrom. Alcoholism 1995; 31 (1–2): 25–38.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratoire de Pharmacocinétique et Toxicologie Clinique, Hôpital Rangueil, 1 Avenue Jean Poulhès, 31403, Toulouse Cedex 4, France

    Sylvie Saivin &  Georges Houin

  2. Equipe ‘Cinétique des Xénobiotiques’, Faculté des Sciences Pharmaceutiques, Toulouse, France

    Sylvie Saivin &  Georges Houin

  3. LIPHA S.A., Centre de Recherche et de Développement de Lyon Lacassagne, Lyon, France

    Thierry Hulot, Sylvie Chabac, Adrian Potgieter & Philippe Durbin

Authors
  1. Sylvie Saivin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thierry Hulot
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sylvie Chabac
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Adrian Potgieter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Philippe Durbin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Georges Houin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saivin, S., Hulot, T., Chabac, S. et al. Clinical Pharmacokinetics of Acamprosate. Clin Pharmacokinet 35, 331–345 (1998). https://doi.org/10.2165/00003088-199835050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199835050-00001

Keywords

Search

Navigation